First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
This study is investigating a new experimental therapy, MP0317, a DARPin® drug candidate
targeting fibroblast activation protein (FAP) and CD40. Preclinical studies suggest that
MP0317 may provide benefit for the treatment of tumors known to express high levels of FAP
and for which approved therapies have been exhausted. This is the first study of MP0317 in
humans and its main purpose is to test its safety and tolerability in patients with advanced
solid tumors. This study will also examine the blood levels of MP0317 at several increasing
dose levels and a recommended dose for further development will be determined. The
recommended dose will be tested in a second part of the study to confirm safety and to
further assess the preliminary biologic and anti-tumor activity.